Zydus Lifesciences extends API acquisition closing date to September 30, 2026

What Zydus Lifesciences announced

On 29 June 2026, Zydus Lifesciences Limited filed a Regulation 30 notice with the BSE informing the market that the closing date for its acquisition of the API business of Sterling Biotech Limited has been extended to on or before 30 September 2026. The extension reflects the parties’ mutual agreement to allow additional time for Sterling Biotech to satisfy remaining conditions precedent under the Business Transfer Agreement (BTA).

"SBL is still in the process of completing certain conditions precedents of the BTA and hence the Company and SBL have executed a letter to extend the closing date by September 30, 2026."

Background of the transaction

In its initial intimation dated 17 September 2024, Zydus Lifesciences disclosed that it had executed a BTA to acquire the API (Active Pharmaceutical Ingredients) business of Sterling Biotech Limited (SBL). The agreement stipulated that the transaction would be completed by 31 December 2024, subject to customary conditions precedent and possible closing‑date adjustments.

A subsequent filing on 24 December 2025 reported that both parties had agreed to push the closing date to 30 June 2026 because some of the stipulated conditions had not yet been fulfilled. The latest notice therefore represents a further extension, moving the expected completion to the end of September 2026.

Extension details and rationale

The filing states that Sterling Biotech is still working on completing certain conditions precedent of the BTA. While the notice does not enumerate these conditions, typical precedents in such transactions include regulatory approvals, third‑party consents, and the transfer of specific assets or licences.

Both companies signed a letter confirming the new deadline, indicating a collaborative approach to resolve the outstanding items. No amendment to the purchase price, payment schedule, or other commercial terms was disclosed.

Key facts at a glance

Why this matters for investors

The extension does not alter Zydus Lifesciences’ capital structure, as the filing makes no mention of share issuances, debt financing, or dilution. However, the delay pushes back the timeline for the company to integrate the API business, which could affect projected synergies and revenue contributions that were previously modelled on a 2024 completion.

From a regulatory standpoint, the company has complied with SEBI’s Listing Obligations by promptly updating the market under Regulation 30. Investors can therefore rely on the disclosed timeline and the acknowledgement that the transaction remains on track, albeit later than originally planned.

Conclusion

Zydus Lifesciences has formally extended the closing date of its acquisition of Sterling Biotech’s API business to on or before 30 September 2026, citing pending conditions precedent on the seller’s side. No financial details of the deal were disclosed, and the extension was communicated through a standard regulatory filing. The transaction remains pending, with the next milestone being the final satisfaction of the BTA conditions and the eventual transfer of the API business.